These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8843225)
1. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. Lakey DL; Treanor JJ; Betts RF; Smith GE; Thompson J; Sannella E; Reed G; Wilkinson BE; Wright PF J Infect Dis; 1996 Oct; 174(4):838-41. PubMed ID: 8843225 [TBL] [Abstract][Full Text] [Related]
2. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358 [TBL] [Abstract][Full Text] [Related]
3. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Powers DC; Smith GE; Anderson EL; Kennedy DJ; Hackett CS; Wilkinson BE; Volvovitz F; Belshe RB; Treanor JJ J Infect Dis; 1995 Jun; 171(6):1595-9. PubMed ID: 7769297 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. Treanor JJ; Schiff GM; Hayden FG; Brady RC; Hay CM; Meyer AL; Holden-Wiltse J; Liang H; Gilbert A; Cox M JAMA; 2007 Apr; 297(14):1577-82. PubMed ID: 17426277 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. Treanor JJ; Betts RF; Smith GE; Anderson EL; Hackett CS; Wilkinson BE; Belshe RB; Powers DC J Infect Dis; 1996 Jun; 173(6):1467-70. PubMed ID: 8648221 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410 [TBL] [Abstract][Full Text] [Related]
8. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice. Liu Q; Xue C; Zheng J; Liu K; Wang Y; Wei Y; Liu GD; Cao Y Vaccine; 2015 Jul; 33(32):4035-40. PubMed ID: 26100927 [TBL] [Abstract][Full Text] [Related]
9. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Keitel WA; Treanor JJ; El Sahly HM; Gilbert A; Meyer AL; Patriarca PA; Cox MM Vaccine; 2009 Dec; 28(2):379-85. PubMed ID: 19879222 [TBL] [Abstract][Full Text] [Related]
10. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Brett IC; Johansson BE Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702 [TBL] [Abstract][Full Text] [Related]
11. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068 [TBL] [Abstract][Full Text] [Related]
12. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. van de Witte S; Nauta J; Montomoli E; Weckx J Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447 [TBL] [Abstract][Full Text] [Related]
13. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Johansson BE; Brett IC Hum Vaccin; 2008; 4(6):420-4. PubMed ID: 18535408 [TBL] [Abstract][Full Text] [Related]
14. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Taylor DN; Treanor JJ; Sheldon EA; Johnson C; Umlauf S; Song L; Kavita U; Liu G; Tussey L; Ozer K; Hofstaetter T; Shaw A Vaccine; 2012 Aug; 30(39):5761-9. PubMed ID: 22796139 [TBL] [Abstract][Full Text] [Related]
15. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Cox MM; Karl Anderson D Influenza Other Respir Viruses; 2007 Jan; 1(1):35-40. PubMed ID: 19453478 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Treanor JJ; Essink B; Hull S; Reed S; Izikson R; Patriarca P; Goldenthal KL; Kohberger R; Dunkle LM Vaccine; 2013 Nov; 31(48):5760-5. PubMed ID: 24075920 [TBL] [Abstract][Full Text] [Related]
17. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987 [TBL] [Abstract][Full Text] [Related]
19. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Quinnan GV; Schooley R; Dolin R; Ennis FA; Gross P; Gwaltney JM Rev Infect Dis; 1983; 5(4):748-57. PubMed ID: 6622889 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Treanor JJ; Wilkinson BE; Masseoud F; Hu-Primmer J; Battaglia R; O'Brien D; Wolff M; Rabinovich G; Blackwelder W; Katz JM Vaccine; 2001 Feb; 19(13-14):1732-7. PubMed ID: 11166898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]